EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability

Valerie Haller, Carina Reiff, Rainer Hamacher, Karina Kostbade, Moritz Kaths, Juergen Treckmann, Stefanie Bertram, Yasmin Zaun, Sebastian Bauer, Johanna Falkenhorst

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05965-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Valerie Haller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital Essen, Essen, Germany. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Protein Kinase Inhibitors, Mutation, Proto-Oncogene Proteins c-kit. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Essen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The prognosis of patients with metastatic GIST and imatinib-sensitive primary mutations has significantly improved. However, limited data are available to inform patients about outcomes across different lines of treatment. This retrospective analysis aims to evaluate patient outcomes at a large German GIST referral center over the past 15 years. Patients and methods Overall survival (OS) and progression-free survival (PFS) were analyzed in patients with metastatic GIST, with diagnosis of metastases between 2008 and 2021, when at least three lines of treatment were available in Germany ( n = 174).

Results

The median overall survival far exceeds historical data for patients with primary exon 11 and exon 9 mutations (median OS in palliative treatment with imatinib: 7.1 years; median OS in second-line palliative treatment with sunitinib: 2.9 years; median OS in third-line palliative treatment with regorafenib: 1.9 years). Among those patients who received palliative imatinib treatment, no significant difference in median OS survival was observed between those who had received perioperative imatinib for localized disease and those who did not. Furthermore, the location of metastases significantly impacted survival, whereas the time between the initial diagnosis and the diagnosis of metastases had no significant effect on survival.

Conclusion

In conclusion, this study provides a novel, real-world reference for survival outcomes in patients with metastatic GIST.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsProtein Kinase InhibitorsMutationProto-Oncogene Proteins c-kitImatinib MesylateHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overGastrointestinal NeoplasmsPrognosisSunitinibNeoplasm MetastasisGermanyPalliative CareSurvival RateYoung AdultProgression-Free SurvivalPhenylurea CompoundsPyridines

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-kitImatinib MesylateKIT protein, humanSunitinibregorafenibPhenylurea CompoundsPyridines

Autor:innen und Institutionen

  • Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital Essen, Essen, Germany.
  • German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
  • Department of Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany.
  • Department of Pathology, University Hospital Essen, Essen, Germany.
  • Department of Medical Oncology and Sarcoma Center, West German Cancer Center, University Hospital Essen, Essen, Germany. sebastian.bauer@uk-essen.de.
  • German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. sebastian.bauer@uk-essen.de.

Förderung

  • Universitätsklinikum Essen

Zitieren

APA

Haller, V., Reiff, C., Hamacher, R., Kostbade, K., Kaths, M., Treckmann, J., Bertram, S., Zaun, Y., Bauer, S., & Falkenhorst, J. (2024). Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05965-2

Vancouver

Haller V, Reiff C, Hamacher R, Kostbade K, Kaths M, Treckmann J, et al. Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05965-2

BibTeX
@article{Haller2024,
  author = {Haller, Valerie and Reiff, Carina and Hamacher, Rainer and Kostbade, Karina and Kaths, Moritz and Treckmann, Juergen and Bertram, Stefanie and Zaun, Yasmin and Bauer, Sebastian and Falkenhorst, Johanna},
  title = {Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05965-2}
}
Kostenlos starten →